Form Type:  8-K
Filing Date:  11/10/2020 
CIK:  0001714899 
Address:  161 OYSTER POINT BLVD. 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 866-8548 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-1.38 (-3.67%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
Trade DNLI now with 

© 2022  
Description of Business
Our goal is to discover, develop and deliver therapeutics to defeat degeneration. Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with neurodegenerative diseases. Recent genetic insights are revealing the underlying biology of neurodegeneration and potential drug targets while enabling better patient selection, similar to how genetic insights have transformed the field of oncology. Our scientific strategy is guided by three overarching principles that we believe will significantly increase the probability of success and accelerate the timing to bring effective therapeutics to patients with neurodegenerative diseases: Genetic Pathway Potential - We select our therapeutic targets and disease pathways based on studies that link human genetic variation to the risk of developing a neurodegenerative disease.
Register and access this filing in:     
  FORM 8-K
      Item 8.01 Other Events.
  EXHIBIT 99.1